<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Allergy Therapeutics — News on 6ix</title>
<link>https://6ix.com/company/allergy-therapeutics</link>
<description>Latest news and press releases for Allergy Therapeutics on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/allergy-therapeutics" rel="self" type="application/rss+xml" />
<item>
<title>Interim Results for six months ended 31 Dec 2025</title>
<link>https://6ix.com/company/allergy-therapeutics/news/interim-results-for-six-months-ended-31-dec-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/interim-results-for-six-months-ended-31-dec-2025-2</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc reported interim revenues of £36.3 million for the six months ended December 31, 2025, a 7% increase from the prior year, driven by the regulatory approval and commercial launch of Grassmuno® in Germany. The company's short-course peanut allergy vaccine candidate, VLP Peanut, met its Phase I/IIa primary endpoint, with Phase IIb planning underway. Financially, the company strengthened its balance sheet and secured a new £40 million senior secured facility post-period end,</description>
</item>
<item>
<title>PDMR Dealings & Shareholding Update</title>
<link>https://6ix.com/company/allergy-therapeutics/news/pdmr-dealings-and-shareholding-update</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/pdmr-dealings-and-shareholding-update</guid>
<pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc announced a reorganisation within ZQ Group involving the transfer of shares between entities, which did not alter the ultimate beneficial ownership. Separately, SkyGem International Holdings Limited placed 209,600,000 shares at an average price of 10 pence per share to four investors, with these shares restricted from AIM market trading for twelve months, a move intended to optimise the shareholder base ahead of a potential dual listing in Hong Kong. Following these tran</description>
</item>
<item>
<title>Positive Biomarker Results from PROTECT Trial</title>
<link>https://6ix.com/company/allergy-therapeutics/news/positive-biomarker-results-from-protect-trial</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/positive-biomarker-results-from-protect-trial</guid>
<pubDate>Wed, 04 Mar 2026 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics PLC announced positive biomarker results from its PROTECT Phase I/IIa trial for VLP Peanut, demonstrating a strong immunomodulating response in peanut-allergic subjects. The trial showed significant reductions in basophil sensitivity and IgE-Fab binding to the main allergen Ara h2, with the highest dose reaching statistical significance. Furthermore, a dose-dependent increase in Ara h2-specific IgG was observed, and a reduction in wheal diameter after skin prick testing was </description>
</item>
<item>
<title>Allergy Therapeutics presents progress at AAAAI</title>
<link>https://6ix.com/company/allergy-therapeutics/news/allergy-therapeutics-presents-progress-at-aaaai</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/allergy-therapeutics-presents-progress-at-aaaai</guid>
<pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc announced scientific progress at the 2026 AAAAI Annual Meeting, presenting positive biomarker and clinical data for Grass MATA MPL, which showed a statistically significant improvement of -22.5% in Combined Symptom Medication Score compared to placebo across Phase III trials, supporting its efficacy and tolerability for seasonal allergic rhinitis. The company also shared supportive short-term safety data from a paediatric cohort in the G308 Phase III trial, demonstrating</description>
</item>
<item>
<title>Update on funding and total voting rights</title>
<link>https://6ix.com/company/allergy-therapeutics/news/update-on-funding-and-total-voting-rights</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/update-on-funding-and-total-voting-rights</guid>
<pubDate>Mon, 23 Feb 2026 07:51:00 GMT</pubDate>
<description>Allergy Therapeutics plc has secured a new £40 million senior secured facility from Hayfin, replacing an uncommitted £20 million facility, which it intends to fully draw down to provide at least 12 months of working capital. This funding, alongside the recent launch of Grassmuno in Germany, supports the company's focus on its proposed Hong Kong listing. Following the full drawdown, Allergy Therapeutics will have £60 million in debt outstanding. Hayfin has also exercised all its warrants and subs</description>
</item>
<item>
<title>Chief Strategy Officer and Board appointments</title>
<link>https://6ix.com/company/allergy-therapeutics/news/chief-strategy-officer-and-board-appointments</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/chief-strategy-officer-and-board-appointments</guid>
<pubDate>Fri, 30 Jan 2026 08:22:00 GMT</pubDate>
<description>Allergy Therapeutics plc has announced the appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and Lawrence Allen Wang as Independent Non-Executive Director, effective January 30, 2026. Helge Weiner-Trapness brings over 30 years of experience from global investment banks, including HSBC Holdings plc, and will focus on driving the company's long-term international growth strategy, corporate development, and partnership strategy. Lawrence Allen Wang, with over 2</description>
</item>
<item>
<title>Result of Annual General Meeting</title>
<link>https://6ix.com/company/allergy-therapeutics/news/result-of-annual-general-meeting-105</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/result-of-annual-general-meeting-105</guid>
<pubDate>Thu, 29 Jan 2026 14:13:00 GMT</pubDate>
<description>Allergy Therapeutics plc announced that all resolutions proposed at its 2026 Annual General Meeting were passed by shareholders, with overwhelming support for the approval of the 2025 accounts, directors' remuneration report, director elections and re-elections, auditor re-appointment, and authorities for share allotment. Specifically, Resolution 1, approving the 2025 Accounts, received 5,820,380,278 votes for, representing 99.99% of the votes cast, with 94.78% of the issued share capital partic</description>
</item>
<item>
<title>Grant of Options under Long Term Incentive Scheme</title>
<link>https://6ix.com/company/allergy-therapeutics/news/grant-of-options-under-long-term-incentive-scheme</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/grant-of-options-under-long-term-incentive-scheme</guid>
<pubDate>Wed, 28 Jan 2026 16:48:00 GMT</pubDate>
<description>Allergy Therapeutics plc announced on January 28, 2026, that it granted share option awards to key management personnel, including persons discharging managerial responsibilities, on January 27, 2026. These options are designed to incentivize long-term value creation and align management interests with stakeholders, with 70% vesting based on Adjusted EBITDA performance and 30% on share price performance over a three-year period. The Chief Executive Officer received 5,409,724 options, and the Chi</description>
</item>
<item>
<title>Half Year Trading Update</title>
<link>https://6ix.com/company/allergy-therapeutics/news/half-year-trading-update-34</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/half-year-trading-update-34</guid>
<pubDate>Mon, 19 Jan 2026 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc reported a strong first half with expected revenues of £36.3 million, a 7% increase on a reported basis, despite phasing out German TAV products, and anticipates full-year revenue growth exceeding the prior year. The company's cash position stood at £10.1 million as of December 31, 2025, following the repayment of shareholder loans, and it has access to £70 million in uncommitted funding. Commercialisation of Grassmuno®, the first new grass pollen immunotherapy in German</description>
</item>
<item>
<title>Notice of 2025 Annual General Meeting</title>
<link>https://6ix.com/company/allergy-therapeutics/news/notice-of-2025-annual-general-meeting-2</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/notice-of-2025-annual-general-meeting-2</guid>
<pubDate>Tue, 06 Jan 2026 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc has published its Notice of Annual General Meeting, seeking shareholder approval for two new board appointments: Helge Weiner-Trapness as Executive Director and Chief Strategy Officer, and Lawrence Allen Wang as Non-Executive Director. These appointments are intended to support the company's exploration of a dual primary listing on the Hong Kong Stock Exchange and its expansion into Asia. Mr. Weiner-Trapness brings over 30 years of experience from major investment banks,</description>
</item>
<item>
<title>Results of General Meeting</title>
<link>https://6ix.com/company/allergy-therapeutics/news/results-of-general-meeting-47</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/results-of-general-meeting-47</guid>
<pubDate>Mon, 29 Dec 2025 13:07:00 GMT</pubDate>
<description>Allergy Therapeutics plc announced that all resolutions were passed at its General Meeting, including the authorization for directors to allot shares up to a nominal amount of £610,000 and to disapply pre-emption rights. These approvals are to facilitate a potential equity raise, which could involve issuing up to 610,000,000 new ordinary shares, approximately 10% of the current issued share capital. The company also posted its Annual Report and Accounts for the year ended 30 June 2025 to shareho</description>
</item>
<item>
<title>Grassmuno® marketing authorisation in Germany</title>
<link>https://6ix.com/company/allergy-therapeutics/news/grassmunor-marketing-authorisation-in-germany</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/grassmunor-marketing-authorisation-in-germany</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc has received marketing authorisation from the German regulatory authority, the Paul Ehrlich Institut, for its subcutaneous grass pollen allergen immunotherapy, Grassmuno®, marking the first such approval under Germany's TAV program. This approval, based on a comprehensive package of quality, safety, and clinical efficacy data, including a significant reduction in the Combined Symptom & Medication Score in a Phase III trial, is expected to drive commercialisation in Germa</description>
</item>
<item>
<title>Authority for allotment of New Shares</title>
<link>https://6ix.com/company/allergy-therapeutics/news/authority-for-allotment-of-new-shares</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/authority-for-allotment-of-new-shares</guid>
<pubDate>Fri, 12 Dec 2025 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc is considering an equity raise to facilitate a potential dual listing on the Hong Kong Stock Exchange, expected in the first half of 2026. To enable this, the company is seeking shareholder approval at a general meeting on December 29, 2025, to allot up to 610,000,000 new ordinary shares, representing approximately 10% of current issued share capital, and to disapply pre-emption rights. Funds raised would support the development of allergy treatments and general corporat</description>
</item>
<item>
<title>Prelim Results and publication of Annual Report</title>
<link>https://6ix.com/company/allergy-therapeutics/news/prelim-results-and-publication-of-annual-report</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/prelim-results-and-publication-of-annual-report</guid>
<pubDate>Thu, 11 Dec 2025 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc reported stable financial performance for the year ended June 30, 2025, with revenue of £55.0 million, broadly flat compared to the previous year, though constant currency revenue grew over 2%. The company experienced an operating loss of £28.2 million, an improvement from £35.3 million in 2024, and an Adjusted EBITDA loss of £9.0 million. Significant post-period events include the full repayment of shareholder loan liabilities and the securing of a new £50 million unsec</description>
</item>
<item>
<title>Primary Safety Endpoint Met in PROTECT trial</title>
<link>https://6ix.com/company/allergy-therapeutics/news/primary-safety-endpoint-met-in-protect-trial</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/primary-safety-endpoint-met-in-protect-trial</guid>
<pubDate>Tue, 09 Dec 2025 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics PLC announced that its Phase I/IIa PROTECT trial has met its primary safety endpoint, with preliminary data from 48 participants showing that a 2000-fold increase in the dose of VLP Peanut was safe and well-tolerated. The trial completed final dosing at the highest planned treatment dose, and data from a second interim biomarker analysis in peanut-allergic patients receiving these highest doses is anticipated in Q1 2026. Preparations are underway for a Phase IIb trial, infor</description>
</item>
<item>
<title>Company to Evaluate Dual Listing on HKEX</title>
<link>https://6ix.com/company/allergy-therapeutics/news/company-to-evaluate-dual-listing-on-hkex</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/company-to-evaluate-dual-listing-on-hkex</guid>
<pubDate>Thu, 06 Nov 2025 07:22:00 GMT</pubDate>
<description>Allergy Therapeutics PLC announced on 6 November 2025 its exploration of a dual primary listing on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX), alongside its existing London Stock Exchange AIM market listing. This strategic move aims to expand the company's presence in Asia, enhance trading liquidity, and broaden its investor base to include Hong Kong and mainland Chinese investors, aligning with its global leadership ambitions in allergy treatments. The company targets the </description>
</item>
<item>
<title>G308 Phase III Year 2 Patient Screening Starts</title>
<link>https://6ix.com/company/allergy-therapeutics/news/g308-phase-iii-year-2-patient-screening-starts</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/g308-phase-iii-year-2-patient-screening-starts</guid>
<pubDate>Thu, 30 Oct 2025 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics has commenced screening for the second year of its Phase III G308 trial, evaluating the long-term efficacy and safety of Grass MATA MPL in paediatric patients. The company aims to complete the screening and randomization period by early Q1 2026. The second year of recruitment aims for a similar number of participants as the first year, in which 190 participants were randomized. Short-term safety data from the first year is expected to be announced in Q4 2025, with a full ana</description>
</item>
<item>
<title>Warrant Exercise and Paydown of Debt</title>
<link>https://6ix.com/company/allergy-therapeutics/news/warrant-exercise-and-paydown-of-debt</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/warrant-exercise-and-paydown-of-debt</guid>
<pubDate>Wed, 29 Oct 2025 07:00:00 GMT</pubDate>
<description>Allergy Therapeutics plc announced that lenders exercised 1,375,000,000 warrants, generating £55 million in proceeds for the company. These proceeds were used to fully repay the principal and accrued interest under the Shareholder Facility. Furthermore, a new £50 million uncommitted loan facility has been agreed with the lenders, providing financial flexibility through to 2030, with interest payable at 12 per cent. per annum and a repayment date of 15 October 2030. Following admission, the compa</description>
</item>
<item>
<title>Further progress in Phase I/IIa PROTECT trial</title>
<link>https://6ix.com/company/allergy-therapeutics/news/further-progress-in-phase-iiia-protect-trial</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/further-progress-in-phase-iiia-protect-trial</guid>
<pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
<description>Allergy Therapeutics announced positive progress in its Phase I/IIa PROTECT trial for its peanut allergy vaccine candidate, VLP Peanut. Dosing has been completed in healthy volunteers, with VLP Peanut being well-tolerated up to the highest planned dose. The final cohort of peanut allergic patients is progressing as planned, showing a supportive safety and tolerability profile. Encouraging dose-dependent biomarker responses and consistent safety data will inform Phase IIb dose selection. A total </description>
</item>
<item>
<title>Grass MATA MPL Publications in Allergy Journal</title>
<link>https://6ix.com/company/allergy-therapeutics/news/grass-mata-mpl-publications-in-allergy-journal</link>
<guid isPermaLink="true">https://6ix.com/company/allergy-therapeutics/news/grass-mata-mpl-publications-in-allergy-journal</guid>
<pubDate>Thu, 31 Jul 2025 06:00:00 GMT</pubDate>
<description>Grass MATA MPL Publications in Allergy Journal.</description>
</item>
</channel>
</rss>